-- 木曜午後遅く、消費関連株が上昇し、ステート・ストリート・コンシューマー・ステープルズ・セレクト・セクターSPDR ETF(XLP)は1.7%、ステート・ストリート・コンシューマー・ディスクレショナリー・セレクト・セクターSPDR ETF(XLY)は1.5%それぞれ上昇した。 企業ニュースでは、オライリー・オートモーティブ(ORLY)の株価は、予想を上回る第1四半期決算を発表した翌日、木曜に7.2%上昇した。 ラム・ウェストン(LW)の株主であるスターボード・バリューは、取締役会宛ての書簡で、同社が投資家向け説明会を開催し、利益を通常の水準に修正すべきだと主張した。ラム・ウェストンの株価は1.6%上昇した。 ウェイフェア(W)の株価は、第1四半期の調整後利益がウォール街の予想を下回ったものの、純売上高は予想を上回ったことを受け、12%急落した。 フォード・モーター(F)のジム・ファーリーCEOは、決算説明会で、米国政府と防衛関連プロジェクトの可能性について初期段階の協議を行っていると述べた。フォード株は1.5%下落した。
Related Articles
Research Alert: Bio: Q1 Results Above Estimates Despite Meaningful Sales/margin Compression
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:BIO delivered Q1 results showing pressure across both segments, with revenue of $592.1M growing 1.1% Y/Y (~$3M above consensus) but declining 4.2% currency neutral. Adjusted EPS of $1.89 fell 25.6% Y/Y yet beat consensus by $0.10, while operating margin deteriorated 420 bps to 6.6% from 10.8% in the prior year. Both Life Science and Clinical Diagnostics segments experienced currency neutral declines due to ongoing academia weakness and Middle East conflicts. Management lowered 2026 guidance, expecting currency neutral revenue of -3.0% to +0.5% growth (down from +0.5% to +1.5%) and operating margin of 10.0%-12.0% (vs. prior 12.0%-12.5%). Despite operational headwinds, BIO maintained strong cash generation with $78.1M in FCF and repurchased ~176K shares. The company's balance sheet remains healthy, with $1.56B in cash and short-term investments, providing financial flexibility amid challenging market conditions, in our view.
ResMed Posts Higher Fiscal Q3 Non-GAAP Earnings, Revenue
ResMed (ASX:RMD) reported Friday fiscal third-quarter non-GAAP earnings of $2.86 per share, up from $2.37 a year earlier.Analysts polled by FactSet expected earnings of $2.80.Revenue for the three months ended March 31 was $1.43 billion, compared with $1.29 billion a year earlier. Analysts surveyed by FactSet expected $1.42 billion.The company expects its fiscal 2026 non-GAAP gross margin to be between 62% and 63%.The board declared a quarterly dividend of $0.60 per share, up from $0.53 a year earlier, payable June 18 to shareholders on record as of May 14.
Research Alert: Gddy: Strong Profitability Metrics Offset By Continued Revenue Headwinds
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:GDDY posted Q1 2026 revenue of $1.2B (+6%), in line with consensus, with EPS of $1.60 beating estimates of $1.52 despite booking deceleration to +2.7% from +5% in Q4. A&C segment growth of +11.6% to $498M showed resilience but continued moderating, while Core Platform remained sluggish at +2.8%. We view booking weakness as concerning given competitive pressures and small business spending constraints that raise questions about growth sustainability. Management reaffirmed 2026 revenue guidance of $5.195B-$5.275B (~6% growth), reflecting limited visibility into booking improvement. However, we see encouraging AI monetization signs with ARPU growth of +9.3% to $246 and Airo AI Builder achieving multi-million dollar annualized bookings within weeks of beta launch. We believe GDDY's impressive margin expansion with NEBITDA margins reaching 32.6% (+210 bps) demonstrates operational discipline, though sustaining A&C growth above 10% remains critical for investor confidence.